Will the Philadelphia Eagles beat the New York Giants at home on November 8, 2026?
4 seats worked this question alone, then argued it out. Code ran every test and computed the number. How the desk works
Judged by Kalshi KXNFLGAME-26NOV08NYGPHI-PHI settlement at 2026-11-08: Kalshi KXNFLGAME-26NOV08NYGPHI-PHI: resolves YES if Philadelphia Eagles win
The dispute that matteredThe committee's four probabilities (0.52, 0.46, 0.52, 0.53) look convergent but are not independent confirmations of a single estimate — they are four different resolutions of one unresolved binary question: does the Kalshi-style price series (d1/d2/d6/d8, values clustering 0.365-0.42) represent the PHI-side or the NYG-side contract? Under one reading PHI is priced ~60-62% (home favorite, consistent with the ~57-60% home-favorite base rate); under the other PHI is priced ~39-40% (home underdog, well below base rate). No analyst ran an actual ticker/contract-metadata pull to settle this — all four explicitly concede it. I resolved it by treating the outcome as genuinely bimodal rather than forcing a point estimate: I give ~55-60% credence to the 'PHI-favorite' reading (on the weak, admittedly circular but still directionally correct basis that PHI's better season record/point differential and home field would ordinarily make it the favorite absent a confirmed negative catalyst, and C's specific ticker-naming evidence nudges toward the '-PHI' suffix denoting the home team's own contract being read correctly as the underdog print by C/D, which I partially discount since C herself flagged this as unconfirmed) against ~40-45% on the underdog reading, landing at a blended ~0.52-0.53 — not a sharp calibrated forecast but the honest expected value across two mutually exclusive world-states, with a wide CI reflecting that the true probability is likely close to 0.40 or 0.60, not actually near 0.52.
Synthesis
- Four post-debate point estimates cluster at 0.46-0.53, with a calibration-weighted log-odds pool of 0.51.
- A numeric price series in the 0.365-0.42 range has been stable-to-slowly-drifting over the final 1-2 days before kickoff, with low variance and high autocorrelation.
- A point-spread series showing PHI favored by 3.0-4.5 points, narrowing toward kickoff.
- An injury-count series for PHI rising to 6 reported items by 11/07.
- Season-long win-rate and point-differential series showing PHI with a higher win rate and positive margin versus NYG's negative margin.
- Calibration-weighted log-odds pooling across the four analysts' post-debate probabilities, producing the deterministic committee number of 0.51.
- Each analyst's internal Bayesian blend across the two mutually exclusive side-attribution readings (e.g., C's 60/40 and A's similar blend), which is a modeled credence split, not an observed fact.
- Historical base-rate heuristics: unconditional NFL home-field win rate ≈0.57; home favorite by ~3 points ≈0.60.
- Whether the 0.365-0.42 price series denotes the PHI-side or NYG-side contract cannot be determined from the supplied data/handles alone; this is the single dominant driver of the spread between 0.40 and 0.62 point estimates across analysts.
- Using season win-rate/point-differential as a tiebreaker for market-price-side-attribution is circular, since an efficient price already embeds those same team-strength statistics.
- A soft Occam's-razor prior (PHI as the statistically stronger home team would ordinarily be the favorite absent a confirmed negative catalyst) mildly favors the 'PHI-favorite' reading of the ambiguous series, but this is a prior, not confirmed evidence.
- PHI beats NYG at home on 2026-11-08 with probability ≈0.53 (committee synthesis), within a credible interval of [0.40, 0.63] reflecting genuine bimodality in the underlying attribution question rather than narrow sampling uncertainty.
- If Kalshi contract metadata is confirmed before kickoff showing the PHI-YES contract trading above 0.55, the estimate should be revised up toward 0.60-0.62; if confirmed below 0.40, revised down toward 0.39-0.40.
- If the official NFL inactive list confirms the Eagles' starting QB or 2+ offensive starters are out, the estimate should be revised down independent of the price-attribution resolution.
- The side-attribution (PHI vs. NYG) of the core market price series (d1/d2/d6/d8), which no analyst resolved via an actual tool/API metadata call.
- Whether the injury-count spike to 6 on 11/06-11/07 reflects a magnitude-relevant (e.g., starter-level) absence or routine roster churn; no event-study or regression quantifies this effect size.
- Whether any of the small-sample auxiliary series (n=3 margin comparisons, regime-split correlations with sign flips) carry genuine signal or are noise, as flagged sharply by Analyst D.
- Whether there is any live tradeable mispricing at all, since C's positioning analysis found the price series converged/low-volatility in the final 24-48h with no open-interest or funding data supplied to assess crowding directly.
| Sports Analyst (A) | 0.27 | Highest domain relevance to sports (1.0) and a defensible home-favorite base rate framing, but n=21 calibration sample is thin and much of A's 'independent' evidence (season win-rate, margin) is conceded by A and D to be circular with the market price. Shares the core price-series ambiguity with B/C/D, so only partial weight for that line. |
| Quantitative Researcher (B) | 0.22 | Largest calibration sample (n=101) and best raw accuracy, strong methodological discipline (explicit correlation check), but B's sports relevance is self-rated lower (0.7), defers almost entirely to an unresolved market read, and the correlation check (d1 vs d7) is not independent of the same side-attribution problem it's meant to validate. |
| Market Positioning Analyst (C) | 0.26 | Contributed the single most concrete new fact this round (the specific Kalshi ticker string), good calibration, and correctly separates the 'no demonstrated edge' positioning conclusion from the side-attribution puzzle. Weighted up for pushing the committee toward an honest blended estimate rather than a false pole. |
| Causal Skeptic (D) | 0.25 | Best Brier score among the four and the most rigorous methodological critique (correctly dismisses n=3 sign-flipping tests and flags the circularity of using season stats to break market-price ties). Slightly discounted for sports-specific relevance (0.8 generalist rating) but given credit for disciplined treatment of uncertainty. |
- Falsified toward ~0.60-0.62 if, before kickoff (2026-11-08), a confirmed Kalshi contract/metadata pull (not ticker-string inference) shows the PHI-YES contract trading above 0.55.
- Falsified toward ~0.39-0.40 if the same confirmed metadata pull shows the PHI-YES contract trading at or below 0.45.
- Falsified (revised down) if the official NFL inactive list, released before kickoff, confirms PHI's starting QB or 2+ offensive starters are out.
- Directly resolved by the game outcome itself: PHI win or loss, observable by approximately 2026-11-08 23:00 UTC.
- The existence of a specific Kalshi contract ticker string (KXNFLGAME-26NOV08NYGPHI-PHI) cited by Analyst C, which is a distinct fact from the price level itself and could in principle be resolved by a metadata pull, though none was performed.
- Analyst A's injury-count series (d4, spiking to 6 reported items on 11/06-11/07), which is a different data type (injury report counts) from the price/spread series and is not duplicated by any other analyst, though its magnitude-to-win-probability translation is unvalidated by any regression or event study.
The seats
Sports Analyst52%
57% NFL home favorite win rate (general home-field + favorite base rate, pre-injury-news)
The handle-to-team mapping for d1/d2/d3/d4/d5 is inferred, not confirmed by metadata; if d1 is actually PHI's own implied probability (not NYG's), the market would be pricing PHI at only ~39.5% — i.e., Eagles as underdogs at home — which would flip the entire thesis and make this a fade-the-favorite / underdog-PHI story instead. Given this ambiguity, my point estimate carries material model risk independent of the sports reasoning itself."
- PHI season win-rate series mean=0.60, consistent with market-implied PHI probability near 60%, supporting PHI as the stronger team.
- PHI margin series mean=+2.9 vs s5 NYG margin mean=-1, consistent with PHI being the better point-differential team this season.
- Kalshi-style probability series (interpreted as NYG implied win prob) rising from 0.365 to 0.395 over the last two days, i.e. PHI implied prob drifting down from ~63.5% to ~60.5%, right as injury counts (d4) spiked to 6 on 11/07.
If the final inactive/injury report released before 2026-11-08 18:00 UTC kickoff confirms Eagles starting QB (or 2+ offensive-line/skill starters) are out and are the entities reflected in the d4 spike to 6 on 11/07, or if Kalshi settlement data later confirms d1 was in fact PHI's own implied probability near 0.395 rather than NYG's, this estimate is falsified and should be revised toward PHI probability ≤0.45."
- d1 series (kalshi_win_prob, mean 0.378, trending to 0.395) represents the Giants' (away team) implied win probability, so PHI's implied probability is ~1-0.395=0.605, consistent with d2 (PHI season win rate 0.60) rather than d3 (NYG 0.368).
- d2 (mean 0.6, binary) = PHI season win indicator series; d3 (mean 0.368) = NYG season win indicator series.
- d7 (mean +2.9 margin) and d8 (mean -1 margin) correspond to PHI and NYG point-differential histories respectively, consistent with PHI being the stronger team.
- d4/d5 (injuries_out/questionable, with d4 spiking to 6 on 2026-11-07) belong to one of the two teams in this matchup but which team is not resolvable from the handle alone; treated as a moderate downside risk factor not yet fully absorbed by the market move in d1.
- d6 (espn_spread) last value 3.0 on game day, down from 4.5 on 10-27, indicates the market line for PHI shrank modestly, consistent with the small d1 drift.
- -0.03 Four independent analysts (A/B one direction, C/D other direction) produced mutually exclusive confident readings (~0.605 vs ~0.395) of the same ambiguous series with no tool able to confirm which side d1 et al. represent; no one supplied actual resolving metadata (ticker/contract label). (Analyst D)
- -0.03 Analyst C's explicit quantified credence split (60% weight that A/B's mapping is correct i.e. PHI~0.605, 40% that own mapping is correct i.e. PHI~0.395), based on a soft Occam's-razor tiebreaker (home-favorite pricing needs no special explanation; underdog pricing would require a confirmed negative catalyst not present in the injury data) -- this is new information beyond my own prior triangulation, which I conceded was circular. (Analyst C)
- -0.02 Analyst B's observation that d2 (the presumed PHI-side legacy price, mean 0.625) is stale (last obs 2026-11-03) while the live-trading series (d1) has been drifting further from 0.365 toward 0.395 over the week -- this is a real directional signal (regardless of side-label) that the market has moved further from the 'PHI strong favorite' story over time, independent of the mapping question. (Analyst B)
- -0.02 My own rebuttal conceding that s2/s4/s5 (season win-rate, point differential) cannot serve as independent tie-breakers for the side-mapping because they are inputs already priced into the market line -- removing a leg I had previously leaned on to justify 0.58. (Analyst A (self))
BASE RATE: Unconditional NFL home-field win rate ≈ 0.57; home favorite by ~3 points historically wins ≈0.60. The single dominant uncertainty in this whole committee discussion is not sporting fundamentals (injuries, rest, form) but a data-attribution problem: which side of the market the ambiguous probability series (d1/d2/d3/d6/d8) represents. Every analyst, including me, independently flagged this as unresolved, and no one ran or had access to a tool call that pulled contract/ticker metadata to settle it. That means my OWN OBJECTION stands unrebutted: this is a case where I should not hold a confident point estimate. OBSERVED: Four analysts split 2-2 on directional reading of the same numeric series (~0.395 vs ~0.605 for PHI), with Analyst C providing the only quantified attempt to break the tie (60/40 in favor of the "PHI favored" reading) using a reasonable but soft prior (Occam's razor: an underdog home-franchise price would need an explicit negative catalyst, which is not confirmed in the injury data at hand). INFERRED: Weighting the two mutually exclusive readings by something close to C's 60/40 split (since no one else offered a sharper discriminator, and I find that heuristic more persuasive than my own earlier circular triangulation via season win-rate/point differential, which I already conceded was invalid) gives a blended estimate: 0.6 × 0.605 + 0.4 × 0.395 ≈ 0.52. UNCERTAIN: This is explicitly a blend across two incompatible world-states, not a single calibrated forecast — the true answer is likely close to either 0.60 or 0.40, not actually 0.52 in reality. I am reporting 0.52 as the best available expected value given unresolved attribution, with low confidence, rather than claiming 0.52 is itself a sharp estimate of team strength. I am moving my probability down from 0.58 toward 0.52 and sharply lowering confidence (0.25) because: (a) my prior 0.58 relied partly on using season win-rate/point-differential as tie-breaking evidence for the mapping, which I now treat as invalid/circular per my own rebuttal; (b) Analyst B's point that the live series has drifted further toward the "underdog" reading over the week (0.365→0.395) without stabilizing back is a real, if weak, directional update against the strong-favorite story, independent of which side it labels; (c) Analyst C's quantified 60/40 credence split is the most defensible attempt in the whole committee to resolve the ambiguity, and applying it mechanically pulls the point estimate meaningfully below my original 0.58. FALSIFICATION CONDITION: This estimate is falsified if, before the 2026-11-08 kickoff (stated as ~18:00-20:30 UTC for a typical Sunday PHI home game; exact kickoff time not confirmed in data), the Kalshi contract ticker KXNFLGAME-26NOV08NYGPHI-PHI is confirmed via its actual settlement/contract metadata to be trading outside the 0.45-0.65 band, or the official NFL inactive list confirms PHI's starting QB or 2+ offensive starters are out — either of which should shift this estimate decisively toward one of the two bimodal poles (≥0.60 or ≤0.40) rather than the blended 0.52.
Quantitative Researcher46%
Loading…
Market Positioning Analyst52%
Loading…
Causal Skeptic53%
Loading…
Claims and evidence
The debate
| Sports | Quanti | Market | Causal | |
|---|---|---|---|---|
| Sports | 0.3 | 0.9 | 0.9 | |
| Quantitative | 0.3 | 0.8 | 0.7 | |
| Market Posit | 0.9 | 0.8 | 0.2 | |
| Causal Skept | 0.8 | 0.6 | 0.5 |
Based on the available series, Philadelphia enters as the stronger team this season (higher season win rate and point differential) and is the home team, with the market-implied probability for the favorite sitting around 60-61% and drifting down slightly (spread narrowing from 4.5 to 3.0) in the final two days before kickoff — likely a partial market reaction to a spike in injuries_out counts on 11/06-11/07. I estimate PHI's true win probability at 0.58, a modest discount to the market-implied ~60.5% to account for the injury signal not yet being handle-confirmed or fully priced, while still anchoring above the generic home-favorite base rate of 0.57.
Market-implied and spread-based pricing put the Eagles (home favorite) at roughly 60-62% to beat the Giants; no out-of-sample predictive test was run on this specific matchup, so I defer heavily to the efficient-market price rather than any independent edge.
The market (as read through d1) already prices Philadelphia as a home underdog at roughly 39-40% to beat New York, with that price having been essentially flat-to-slightly-rising over the final day before kickoff and showing low volatility/high autocorrelation — signs of a converged, reasonably efficient market rather than one with an obvious mispricing. Absent a confirmed independent higher-confidence fundamental signal, the tradeable edge for betting PHI (or against it) based on 'Eagles are home, should win' reasoning is largely already absorbed into the 39.5% print; the base rate for home-field advantage (~57%) has clearly been overridden by team-strength/injury information embedded in the market itself.
None of the supplied statistical tests establish a causal or even robustly correlational link between the available performance/indicator series and the game outcome — the regime-split correlations flip sign (s1, s8), the n=3 tests are driven by a single observation and have perfect autocorrelation (s2, s3, s6), the binary comparison is statistically insignificant (s4), and the conditional signal never fires (s7). The only data series with enough sample size and low noise to lean on at all is the market price (d6/d8), which — if correctly attributed to the PHI side — implies the market views Eagles as a ~40% home underdog, below the ~57% unconditional home-win base rate. I update modestly below the base rate toward the market-implied figure, but with wide uncertainty because the side-attribution of d6/d8 is not confirmed and could reverse the conclusion.
- methodological 0.3B defers entirely to the market price with no independent discount, treating the ~60-62% market-implied figure as the final estimate. I apply a discount to ~0.58 to account for the injury signal (d4 spike to 6 on 11/07) not yet being fully absorbed into the price. B's own objection notes the same staleness/drift issue I flag but B doesn't adjust the point estimate for it, just flags it as risk. This is a disagreement about whether to mechanically repeat the market price or make a small independent adjustment on top of it.
- assumption 0.2B treats d7 (spread series, latest 3.0) as confirming ~60% via a generic '3-pt home favorite' heuristic, while I read the spread move (4.5->3.0) as itself a market reaction to the injury news, i.e. evidence of an underreaction/discount being partially priced, not just corroboration of a static 60% number. Same data, different causal reading.
- assumption 0.9C assumes d1 is directly the PHI-win contract price (converged near 0.395, PHI as home underdog), the opposite side-mapping from my assumption that d1 is the NYG-side price (implying PHI ~0.605). This is the same core handle-ambiguity both of us flag as our own objection, but we resolve it in opposite directions, which flips the entire directional conclusion (PHI favorite vs. PHI underdog).
- interpretation 0.5C reads low volatility/high autocorrelation in d1 near 0.395 as evidence of a 'converged, efficient' market price that has already absorbed all team-strength and injury information. I read the same type of recent drift (if d1 is NYG-side, rising 0.365->0.395, i.e., PHI falling 63.5%->60.5%) as a market still actively reacting to injury news, not yet settled -- an active-adjustment regime rather than a converged one.
- assumption 0.9D assumes d6/d8 represent the PHI-side contract price (mean ~0.4145, converging to 0.395-0.40), implying PHI is a ~40% home underdog -- the same side-mapping issue as with Analyst C, opposite to my assumption that the analogous series (d1 in my labeling) is NYG-side, implying PHI near 60%. Same unresolved ambiguity, opposite resolution, directly conflicting conclusions about favorite/underdog status.
- methodological 0.3D dismisses nearly all other series (s1-s8 regime splits, n=3 tests, binary comparisons) as too noisy/underpowered to use, and leans almost entirely on the price series alone. I give more weight to the season win-rate (s2) and margin (s4 vs s5) series as corroborating (not independent, but consistent) signals for PHI being the stronger team, rather than treating them as uninformative just because small-sample significance tests on them are weak. This is a disagreement about how much evidentiary weight small-sample descriptive series should carry when they are directionally consistent with the price-based read.
- assumption 0.8C asserts d1 is the PHI-side contract price (~0.395, making PHI a ~40% home underdog), directly contradicting my assumption that d1 is the NYG-side implied probability (~0.395), whose complement gives PHI ~0.605. This is the same underlying series interpreted with opposite sign/attribution — it cannot be reconciled by more data analysis alone, only by checking the actual Kalshi ticker/side metadata, which none of us have done. If C is right, my entire 0.60-0.625 estimate flips to ~0.40.
- assumption 0.7D reads d6/d8 (a tight, low-variance ~0.395-0.415 series) as the PHI-side market price, concluding PHI is priced as a ~40% underdog. If d6/d8 is the same underlying feed as my d1 (plausible given near-identical values and range), this is the identical side-attribution conflict I flagged with C: same numbers, opposite team assigned to them. Severity is high because it is a binary attribution error, not a matter of degree.
- methodological 0.3A takes the market-implied ~60.5% PHI probability and manually discounts it to 0.58 to account for an injury-count spike (d4=6 on 11/07), without running any event study or regression showing injury-count spikes of this magnitude historically shift win probability by ~2.5pp. This is an ad-hoc narrative adjustment layered on top of an already efficient price, not a validated effect size — I would flag this discount as unsupported by any test in evidence.
- interpretation 0.2A cites s2 (PHI season win-rate mean=0.60) as 'consistent with' the market-implied ~60% probability and treats this as corroborating evidence. A team's unconditional season win rate and a single-game market-implied probability are different statistics measuring different things (season-long base rate vs. matchup-specific conditional price); treating their numerical similarity as cross-validation (as A does, and as I did with d1 vs d7 spread-implied odds) is a weaker form of corroboration than mine, since win-rate and market price aren't argued to be mathematically complementary the way home-favorite-spread and moneyline-probability are.
- methodological 0.3D dismisses the margin/power-rating differential series (s2, s3, s6) as unreliable due to n=3 and sign flips, but does not attempt the complementary cross-check I ran (s5: correlating the implied-probability series against the point-spread series to confirmed they tell the same story at -0.985). By relying solely on d6/d8 without an independent corroborating series, D's estimate has less internal cross-validation than mine, even though we disagree on which side d6/d8 (vs. my d1) actually represents.
- methodological 0.3C treats the market price as fully calibrated/efficient (citing low volatility and high autocorrelation as evidence of 'convergence') and concludes no edge exists either way. This begs the side-attribution question: C's efficiency argument is only valid once the side attribution is resolved, which C themselves flags as unresolved in their own objection. I weight the spread series (d7) as an independent check on direction; C does not use d7 at all to adjudicate.
- assumption 0.9A assumes d1 (the 0.365→0.395 series) represents the Giants' (away team) implied win probability, implying PHI is ~60.5% to win. I read the identical d1 series as the PHI-side contract price itself (i.e., PHI implied ~39.5%). We are looking at the same numeric series and reaching opposite directional conclusions purely on handle-to-side mapping, which neither of us can confirm from metadata. This is the single largest swing factor in the whole committee's estimates.
- methodological 0.4A anchors to the unconditional home-favorite base rate (0.57) and treats the market price as a 'modest update' above it, whereas I treat the market price itself as the already-fully-conditioned estimate and argue the raw home-field base rate is not a meaningful adjustment once a liquid market price exists.
- assumption 0.8B also assumes d1 is the NYG-side price (PHI complement ≈0.605) and uses d7 (spread, PHI -3) as independent corroboration. I read d1 as the PHI-side price directly (~0.395), which would make d7's spread sign, if real, inconsistent with a 39.5% PHI win probability — i.e., we can't both be right about which team d7 favors either.
- methodological 0.3B leans on d2 (PHI-side price, mean 0.625, stale since 11/03) as cross-validation despite acknowledging it is 5 days stale and diverging from d1's recent trend; I would not treat a stale, non-converging series as confirmatory evidence for a 1-day-horizon price estimate — recency matters more than correlation coefficients computed over a period that includes stale data.
- interpretation 0.2D's conclusion (PHI ~39-40% via d6/d8) is directionally consistent with my own reading of d1, but D frames this with wide residual uncertainty due to unresolved side-attribution, while I weight the low variance/high autocorrelation of the price series more heavily as evidence the market has actually converged and the attribution is more likely correct (PHI as home underdog) than not.
- methodological 0.1D dismisses most of the auxiliary performance/margin series (s1-s7) as statistically unreliable (sign-flipping, n=3, insignificant) and leans almost entirely on the price series; I did not independently vet those auxiliary tests but implicitly agree they add little once a converged market price exists — this is low-severity because it's actually convergent reasoning, not a real conflict.
- assumption 0.8A assumes d1/s1 is the NYG-side implied probability (so PHI ≈ 0.605), which is the opposite attribution from my reading of the same price series (d6/d8) as the PHI-side price (≈0.395-0.40). This is an unresolved sign/side-attribution ambiguity, not a resolved fact — A's entire 0.58 estimate flips to ~0.40 under my attribution, and A even flags this in their own objection without resolving it. Neither of us has metadata confirming the correct side.
- methodological 0.6A treats PHI's higher season win-rate (s2) and point-differential (s4 vs s5) as independent corroborating evidence for the market-implied probability. These are not independent: if the market is even weakly efficient, season record and point differential are already baked into the price. Citing them as separate confirmation is circular/double-counting the same latent 'team strength' variable, not an out-of-sample validation.
- methodological 0.5A infers a causal link between the injuries_out spike to 6 on 11/07 and the two-day price drift (0.635→0.605 PHI-implied), but this is two data points of co-movement with no test ruling out coincidence, unrelated line movement (e.g., public betting flow, weather), or the injuries belonging to the Giants rather than the Eagles (A admits the team mapping is unresolved). No placebo/event-study test was run to show injury-count spikes generally move this price series.
- methodological 0.5B's 'cross-validation' via the -0.985 correlation between d1 and d2 is not informative: if d1 and d2 are complementary quotes for the same binary event (as B assumes), near-perfect negative correlation is a mathematical artifact of the construction (p+q≈1), not an independent confirmation of the 0.60-0.625 estimate. B partially acknowledges this (autocorrelation-inflated) but still counts it as corroborating evidence.
- factual 0.6B asserts d1 is the NYG-side probability and d2 the PHI-side probability, the same unresolved side-attribution issue as with Analyst A, and inconsistent with Analyst C's reading that d1 itself is the PHI-win contract price (~0.395). All three readings of the same handles cannot be simultaneously correct.
- methodological 0.4B leans on a 'spread-to-win-probability heuristic' (3pt favorite ≈ 60%) as the base rate itself, then treats the live market price as confirming that heuristic-derived base rate — but the heuristic was estimated on a different population (historical NFL spread outcomes across all games) and its applicability to this specific team/season/injury context is untested; no regime split or holdout test was run to confirm 60% still holds when the line is this volatile (B's own objection flags the d1 drift toward NYG as undermining the heuristic's currency).
- interpretation 0.5C interprets low volatility/high autocorrelation in d1 as evidence the market has 'converged' and is efficient. An equally consistent alternative explanation not ruled out: a thin/illiquid prediction market with few trades would show the same low-variance, high-autocorrelation signature simply from lack of order flow, not from information aggregation. No volume/liquidity data was supplied to distinguish these, so 'efficiency' is an unverified inference from price shape alone.
- assumption 0.4C's base rate ('a team priced at ~39-40% wins ~38-42% of the time, markets are historically well-calibrated') imports sportsbook calibration statistics onto a Kalshi prediction-market contract price without testing whether this specific market type/venue exhibits the same calibration; this is a regime-transfer assumption that was never tested on Kalshi NFL contracts specifically.
- methodological 0.5None of the four of us (myself included) has run a placebo/random-date event study, a regime split of the price series around known injury-news events, or an influence test to check whether the 0.395-0.40 reading is driven by a single outlier print or a genuine stabilized level. We are all reading the same ambiguous handle and defaulting to 'the market is probably right' without an independent test of calibration for this contract series.
I concede the core point: this is not resolvable from the handle names alone, and it is the single largest swing factor in my estimate — flipping PHI from a ~58% favorite to a ~40% underdog is not a minor adjustment, it reverses the pick entirely. My OWN OBJECTION already flagged this, which is itself an admission that my point estimate (0.58) was asserted with more confidence than the underlying evidence supports. I did try to triangulate using s2 (PHI season win-rate ~0.60) and s4/s5 (point differential) as a tie-breaker to prefer the 'd1=NYG' reading — but Analyst D's separate methodological challenge is also correct that this triangulation is circular: season win-rate and point differential are inputs already priced into the market line, so using them to disambiguate which side of the market line is which is not independent corroboration, it's assuming the conclusion (PHI is good) to resolve an ambiguity about what the market is pricing. So I cannot actually defend 0.58 as more justified than D's ~0.40 reading using the tools I've run so far. The honest position is: given unresolved side-attribution, my estimate should be stated as a bimodal/wide-uncertainty range (roughly 0.40–0.60) rather than a confident 0.58, until the mapping is confirmed.
This challenge is correct that I cannot adjudicate the side-attribution from the data series alone, and I did not run the one test that would resolve it: pulling the tool/column metadata (ticker name, contract description) for d1 and d2 to confirm which side each quotes. Three analysts (A, B/me, C) have produced three mutually inconsistent readings of the same handles — that alone is proof the attribution was asserted, not verified, by at least two of us. I accept that my -0.985 correlation claim (challenge from Analyst D) is also void as "cross-validation": if d1+d2≈1 by construction, near-perfect negative correlation is mechanical, not confirmatory, regardless of which side is which. So two of my three evidentiary legs (d1/d2 labeling, and their correlation as validation) are compromised. Where I partially hold ground: d7, the point-spread series, is less ambiguous in its sign convention than probability-handle labels, because spreads are conventionally reported as (favored team, negative number) and the magnitude (3.0) only makes sense as a near-even-game line for a game between two single-digit-point-differential teams — it would be a very unusual coincidence for a mislabeled d7 to still produce a plausible home-favorite-by-3 story with the home team (PHI) also being the team with the better recent power rating (per d3/d4, despite their noise). That is weak, inferential corroboration, not proof. Net: I cannot currently distinguish between (a) PHI is -3 favorite at ~60-62% [my original thesis] and (b) the labels are reversed and PHI is actually priced near 39.5% [Analyst C's reading]. Those are not close calls — they're opposite conclusions. Without resolving metadata, my point estimate should be stated as bimodal/unresolved rather than confidently ~0.60-0.625.
This challenge is correct that the side-mapping is the single load-bearing assumption in my thesis, and I flagged it myself as an unresolved own-objection rather than something I had verified. I do not have an independent way to adjudicate it from the price series alone — a converged, low-volatility, high-autocorrelation series looks identical whether it's labeled PHI-side at 0.395 or NYG-side at 0.395 (implying PHI 0.605). Both A and B are each equally confident in the opposite direction, which itself is evidence the series is genuinely ambiguous without ticker metadata, not that one of us is obviously right from priors. However, I'll note one soft tiebreaker I did not weight enough: Philadelphia is nominally the stronger/more successful franchise recently and is at home, so a market pricing them at 0.395 (A/B's read, i.e., underdog) would require a specific negative catalyst (e.g., QB injury) to justify, whereas 0.605 (home favorite) requires no special explanation. Absent that catalyst being independently confirmed in d4-d7, Occam's razor leans toward PHI being the ~0.605 favorite, which would mean my positioning conclusion (price already reflects convergence) still holds, but my directional number (39.5% for PHI) is more likely wrong than A's/B's (60.5%). I shift roughly 60% credence to A/B's mapping being correct, 40% to mine.
I cannot rebut this — it targets the exact unresolved ambiguity I flagged as my own objection, and A/B have independently converged on the opposite resolution of the same data. The fact that three analysts (A, B, D) are looking at near-identical numeric series (~0.40 vs ~0.60 complements) and assigning sides by assumption rather than by verified label is itself the strongest evidence that none of us have ruled out the confounder: we are pattern-matching "which number looks more PHI-like" rather than reading a documented contract ID. That is leakage of our priors into the labeling, not evidence from the data. Critically, A assumes the opposite mapping from me with equal confidence, which means at least one of us is wrong, and the data as supplied gives no tool output (e.g., a metadata field, ticker string, or settlement description) that discriminates between the two readings. This is a case where I should not claim I have 'a' probability update from this series at all until attribution is fixed — my 0.40ish estimate and A's implied 0.60ish estimate are not two different inferences from the same evidence, they are two guesses filling the same gap, and my falsification condition (check the actual Kalshi ticker) is the only thing that resolves it, not further argument between us.
- -0.03 Four independent analysts (A/B one direction, C/D other direction) produced mutually exclusive confident readings (~0.605 vs ~0.395) of the same ambiguous series with no tool able to confirm which side d1 et al. represent; no one supplied actual resolving metadata (ticker/contract label).
- -0.03 Analyst C's explicit quantified credence split (60% weight that A/B's mapping is correct i.e. PHI~0.605, 40% that own mapping is correct i.e. PHI~0.395), based on a soft Occam's-razor tiebreaker (home-favorite pricing needs no special explanation; underdog pricing would require a confirmed negative catalyst not present in the injury data) -- this is new information beyond my own prior triangulation, which I conceded was circular.
- -0.02 Analyst B's observation that d2 (the presumed PHI-side legacy price, mean 0.625) is stale (last obs 2026-11-03) while the live-trading series (d1) has been drifting further from 0.365 toward 0.395 over the week -- this is a real directional signal (regardless of side-label) that the market has moved further from the 'PHI strong favorite' story over time, independent of the mapping question.
- -0.02 My own rebuttal conceding that s2/s4/s5 (season win-rate, point differential) cannot serve as independent tie-breakers for the side-mapping because they are inputs already priced into the market line -- removing a leg I had previously leaned on to justify 0.58.
BASE RATE: Unconditional NFL home-field win rate ≈ 0.57; home favorite by ~3 points historically wins ≈0.60. The single dominant uncertainty in this whole committee discussion is not sporting fundamentals (injuries, rest, form) but a data-attribution problem: which side of the market the ambiguous probability series (d1/d2/d3/d6/d8) represents. Every analyst, including me, independently flagged this as unresolved, and no one ran or had access to a tool call that pulled contract/ticker metadata to settle it. That means my OWN OBJECTION stands unrebutted: this is a case where I should not hold a confident point estimate. OBSERVED: Four analysts split 2-2 on directional reading of the same numeric series (~0.395 vs ~0.605 for PHI), with Analyst C providing the only quantified attempt to break the tie (60/40 in favor of the "PHI favored" reading) using a reasonable but soft prior (Occam's razor: an underdog home-franchise price would need an explicit negative catalyst, which is not confirmed in the injury data at hand). INFERRED: Weighting the two mutually exclusive readings by something close to C's 60/40 split (since no one else offered a sharper discriminator, and I find that heuristic more persuasive than my own earlier circular triangulation via season win-rate/point differential, which I already conceded was invalid) gives a blended estimate: 0.6 × 0.605 + 0.4 × 0.395 ≈ 0.52. UNCERTAIN: This is explicitly a blend across two incompatible world-states, not a single calibrated forecast — the true answer is likely close to either 0.60 or 0.40, not actually 0.52 in reality. I am reporting 0.52 as the best available expected value given unresolved attribution, with low confidence, rather than claiming 0.52 is itself a sharp estimate of team strength. I am moving my probability down from 0.58 toward 0.52 and sharply lowering confidence (0.25) because: (a) my prior 0.58 relied partly on using season win-rate/point-differential as tie-breaking evidence for the mapping, which I now treat as invalid/circular per my own rebuttal; (b) Analyst B's point that the live series has drifted further toward the "underdog" reading over the week (0.365→0.395) without stabilizing back is a real, if weak, directional update against the strong-favorite story, independent of which side it labels; (c) Analyst C's quantified 60/40 credence split is the most defensible attempt in the whole committee to resolve the ambiguity, and applying it mechanically pulls the point estimate meaningfully below my original 0.58. FALSIFICATION CONDITION: This estimate is falsified if, before the 2026-11-08 kickoff (stated as ~18:00-20:30 UTC for a typical Sunday PHI home game; exact kickoff time not confirmed in data), the Kalshi contract ticker KXNFLGAME-26NOV08NYGPHI-PHI is confirmed via its actual settlement/contract metadata to be trading outside the 0.45-0.65 band, or the official NFL inactive list confirms PHI's starting QB or 2+ offensive starters are out — either of which should shift this estimate decisively toward one of the two bimodal poles (≥0.60 or ≤0.40) rather than the blended 0.52.
- -0.10 C's explicit identification of the data source as ticker 'KXNFLGAME-26NOV08NYGPHI-PHI' — Kalshi's naming convention appends the settlement side to the ticker, so a '-PHI' suffix structurally indicates this is the PHI-wins contract, meaning d1's ~0.395 print is PHI's own implied win probability, not NYG's complement
- -0.05 D's d6/d8 cross-check showing the same ~0.395-0.40 value is tight and low-variance across two near-identical series, which is consistent with this being one real, converged contract price (reinforcing that the ticker-based reading is a stable market state, not a noisy single print)
- -0.03 A's concession that using season win-rate/point-differential (s2/s4/s5) to disambiguate which side d1 represents is circular — those stats are themselves priced into the line, so they cannot serve as independent corroboration for the 0.605 reading as I had used them
- +0.02 Internal inconsistency I flagged: d7 (spread -3 PHI favored, historically ~60% win rate) is incompatible with a ~39.5% PHI implied probability from the ticker reading; since neither series' sign convention is tool-confirmed, this contradiction lowers confidence in any single point estimate and pulls the mean back toward 0.50 rather than fully committing to 0.395
BASE RATE: NFL home favorites win ~57-60% historically (standard spread-to-probability heuristic); unconditional home-field win rate ~57%. OBSERVED: Across the committee, no one has run the one decisive test — an actual metadata/API lookup confirming which side of the Kalshi contract d1/d2 (or d6/d8) represent. All four analysts admit this is the single load-bearing, unresolved assumption, and two mutually exclusive readings (PHI≈60% vs PHI≈39.5%) have been asserted with equal confidence by different analysts using the same underlying numbers. INFERRED: The strongest new piece of evidence in this round is C's naming of the specific ticker string, "KXNFLGAME-26NOV08NYGPHI-PHI." Kalshi's standard convention is that the market ticker suffix denotes the settlement side of the YES contract — a "-PHI" suffix would denote the PHI-wins-YES contract. If that convention holds, d1's ~0.395 print is PHI's own win probability (home underdog), not NYG's complement as I originally assumed. This is genuinely new information (a specific identifier string) rather than a repeated assertion, so it warrants a real update, though I did not independently verify the convention via a tool call — I am relying on C's transcription of the ticker, which itself is not a confirmed metadata pull. MODELED/PREDICTED: Weighting ~65-70% credence that the ticker convention is being read correctly (d1 = PHI-side, ~39.5%) against ~30-35% that my original NYG-side reading holds (PHI ~60.5%), and pulling back toward the midpoint given the unresolved contradiction with the d7 spread evidence (which independently suggests a ~60% home-favorite story), my point estimate shifts from 0.605 down to approximately 0.46 — close to a coin flip, reflecting that the committee has moved from "confident home favorite" toward "genuinely bimodal, with a modest lean toward underdog" without fully resolving it. UNCERTAIN: The side-attribution of the Kalshi price series remains unconfirmed by any actual tool/API metadata call. No one in this round ran that test. My estimate and confidence are both lowered to reflect that this is an update under real ambiguity, not a resolved fact. FALSIFIED IF: If a confirmed Kalshi API/metadata pull (contract description field, not ticker-string inference) before kickoff shows the PHI-YES contract trading above 0.55, revise back up toward 0.60; if it confirms trading at or below 0.40, revise down to ~0.40 with high confidence. Also falsified/revised if the final injury report confirms a QB-level Eagles absence consistent with A's d4 injury-spike evidence, which would independently support the lower (underdog) estimate regardless of ticker-attribution resolution.
- +0.10 d7: point-spread sign convention (favored team quoted negative) is a less ambiguous handle than probability-series labels; magnitude 3.0 is plausible as PHI-favored given PHI's better recent point differential (s4/s5)
- -0.02 Concession that season win-rate/point-differential (s2,s4,s5) cannot be used to disambiguate side-attribution because they are already priced into the line (circularity)
- +0.04 Explicit concession that the 0.58 PHI-favorite estimate should be stated as a wide bimodal 0.40-0.60 range given unresolved attribution, rather than confidently above base rate
- +0.00 Demonstration that three analysts independently pattern-matched opposite side-attributions with equal confidence and no tool actually returned ticker/contract metadata to resolve it
Base rate: NFL home team wins ~57-58% unconditionally; once a correctly-attributed market price is observable, it should dominate as the calibrated estimate. My entire original thesis rested on treating d1 as the PHI-side price (0.395, underdog), which I flagged myself as the single largest vulnerability. In my rebuttal I already moved to 60% credence that A/B's reversed mapping (PHI as ~0.605 home favorite) is correct, based on a soft Occam's-razor argument (PHI's recent strength + home field would ordinarily make it the favorite absent a confirmed negative catalyst). Nothing in this round resolves the mapping with hard metadata -- no analyst pulled an actual contract ticker or settlement description, which all four of us now explicitly concede is the only thing that would settle this. Given that, the honest move is to blend rather than pick a pole. B's argument that the point-spread handle (d7) has a more conventional, less-ambiguous sign convention than the probability-series handles is the one genuinely new piece of reasoning this round that nudges further toward the PHI-favorite reading (favored team negative, magnitude 3.0 fitting a near-even game between two single-digit-differential teams). D's point that using season win-rate/point-differential to pick a side is circular (those stats are themselves priced into the line) pulls slightly back against over-trusting the 'PHI should be favored' intuition. A's concession that the honest estimate is a 0.40-0.60 bimodal range reinforces that the correct output is a blended, lower-confidence midpoint, not either pole. Blending a ~35% weight on the 0.395 reading with a ~65% weight on the 0.605 reading nets to roughly 0.52 -- essentially a coin flip, which correctly reflects genuine unresolved directional ambiguity in the data, not a toss-up on football merits. On the positioning question itself (my actual mandate): regardless of which mapping is correct, every analyst's own data shows the relevant price series (whichever side it is) is low-volatility, high-autocorrelation, and converged in the final 24-48h -- no one has produced evidence of a live mispricing or crowding imbalance (no open interest/funding data was even supplied), so the crowding/edge conclusion stands: there is no demonstrated tradeable edge beyond resolving which side the number is actually on, which is a data-sourcing problem, not an alpha signal. Falsification: if the Kalshi KXNFLGAME-26NOV08NYGPHI-PHI contract's actual last-trade price before kickoff is confirmed via ticker/contract metadata to be below 0.45 or above 0.65, this blended 0.52 estimate and the 'market already converged, no edge' positioning thesis should be revised toward that confirmed print rather than the blend.
- +0.00 Analyst A's concession that triangulating via season win-rate/point-differential to resolve the d1/d2 side-mapping is circular (those stats are already priced into the line), so A's 0.58 estimate cannot be defended as better-justified than my 0.40 reading — A now states the honest range is 0.40-0.60.
- +0.00 Analyst B's concession that the -0.985 correlation claim is mechanical (d1+d2≈1 by construction) and void as 'cross-validation' of side-attribution, and that the spread-sign argument (d7) is only 'weak, inferential corroboration, not proof' — removes the strongest attempted tiebreaker toward the PHI-favorite reading.
- +0.13 Analyst C's explicit concession shifting ~60% credence toward the A/B mapping (PHI favorite ~0.605) based on an Occam's-razor argument that a 0.395 PHI price would require an unconfirmed negative catalyst while a 0.605 price needs no special explanation.
Base rate: unconditional NFL home-team win rate ~0.57. My prior estimate (0.40) was conditional on a specific, unverified reading of d6/d8 as the PHI-side contract price — a reading I flagged myself as unconfirmed and possibly reversed. All four analysts, including the two (A, B) who originally read the series the opposite way, now explicitly concede that the side-attribution cannot be resolved from the supplied handles/metadata alone, and that the two attempted tiebreakers (A's season-win-rate/margin triangulation, B's spread-sign and correlation arguments) are either circular (already priced into the line being disambiguated) or mechanical artifacts, not independent evidence. This confirms my original challenge: nobody has ruled in or out either side of a binary, symmetric ambiguity, so neither the 0.40 nor the 0.60 reading is better supported by the data as given. The only genuinely new piece of information is Analyst C's voluntary shift of ~60% credence toward the PHI-favorite (0.605) mapping, based on a soft prior/Occam's-razor argument. I weight this lightly: it is not independent confirmed evidence (no ticker metadata, no injury report was produced by any tool), it is the same kind of prior-driven reasoning I already criticized A for using circularly, and C explicitly frames it as a soft tiebreaker, not a resolution. I give it a modest delta (+0.13) rather than fully adopting it, because treating three analysts' unverified priors as converging evidence risks exactly the leakage-of-priors problem I flagged in my rebuttal — three people independently leaning toward 'PHI is probably the stronger/favored team' is weak correlated evidence (shared base-rate intuition), not three independent confirmations. Net effect: without confirmed attribution, the responsible position is to treat the market-price evidence as largely uninformative for distinguishing 0.40 from 0.60, and move from my prior 0.40 toward something close to (but still slightly below) the unconditional home-field base rate (0.57), reflecting the mild aggregate lean toward PHI-as-favorite that even the skeptics converged on, while keeping confidence low given the unresolved core data-attribution problem. Falsification condition unchanged: if the documented Kalshi KXNFLGAME-26NOV08NYGPHI-PHI contract's last traded price before kickoff is confirmed (via ticker/contract metadata, not inference) to be below 0.45 or above 0.65, this estimate should be revised to match that confirmed price directly.
SYNTHESIS: The committee's apparent convergence (0.46-0.53, pooled 0.51) masks the fact that nearly all cited evidence reduces to ONE ambiguous data series whose side-attribution (PHI vs. NYG) was never confirmed via metadata — all four analysts admit this. Treating the four estimates as independent confirmations would overstate confidence; correctly, this is a single binary attribution question with two incompatible resolutions (PHI ≈0.60-0.62 favorite, or PHI ≈0.39-0.40 underdog), each internally consistent with the home-favorite base rate (0.57-0.60) or a well below-base-rate market signal respectively. I weight Analyst D and C highest for disciplined treatment of this ambiguity (D for rigorously dismissing circular/underpowered auxiliary tests, C for producing the one new concrete fact — the ticker string — and for the sharpest attempt to quantify a credence split rather than pick a pole). A and B get moderate weight: A for sports-domain relevance despite a thin calibration sample and some circular corroboration (season stats), B for the largest calibration sample but excessive reliance on an unresolved price read with no independent discount. CONSENSUS: 0.53, CI [0.40, 0.63]. This is explicitly a probability-weighted blend across two mutually exclusive world-states, not a sharp calibrated forecast of team strength — the true resolution is more likely close to 0.40 or 0.60 than to 0.52 itself. TRADEABILITY: Not tradeable as stated. The one positioning-relevant finding (C's) is that the ambiguous price series shows low volatility and high autocorrelation — i.e., no evidence of an active mispricing or crowding imbalance in either direction, and no open-interest/funding data was supplied to check further. Until the side-attribution is resolved via an actual contract/metadata lookup, there is no actionable directional edge distinguishable from a coin flip with unknown sign. Expected return ≈0.0: I cannot propose a position (e.g., buy PHI-YES or NYG-YES on Kalshi) without first running the one test nobody in this committee executed — pulling the contract's settlement description field. Recommended action: before any capital commitment, resolve the ticker/contract metadata question directly; only then does this become a tradeable view (likely a near-zero-edge hold-to-market-price position given C's convergence finding, regardless of which side wins the attribution debate).
Assumptions
- reviewd1 series (kalshi_win_prob, mean 0.378, trending to 0.395) represents the Giants' (away team) implied win probability, so PHI's implied probability is ~1-0.395=0.605, consistent with d2 (PHI season win rate 0.60) rather than d3 (NYG 0.368).
- reviewd2 (mean 0.6, binary) = PHI season win indicator series; d3 (mean 0.368) = NYG season win indicator series.
- reviewd7 (mean +2.9 margin) and d8 (mean -1 margin) correspond to PHI and NYG point-differential histories respectively, consistent with PHI being the stronger team.
- reviewd4/d5 (injuries_out/questionable, with d4 spiking to 6 on 2026-11-07) belong to one of the two teams in this matchup but which team is not resolvable from the handle alone; treated as a moderate downside risk factor not yet fully absorbed by the market move in d1.
- reviewd6 (espn_spread) last value 3.0 on game day, down from 4.5 on 10-27, indicates the market line for PHI shrank modestly, consistent with the small d1 drift.
- reviewd1 represents NYG-side market-implied win probability and d2 represents PHI-side, complementary to ~1.0 after vig removal
- reviewd7 is the current point-spread line (PHI -3 to -4.5) and is a reasonable proxy for market consensus
- reviewNo injury, weather, or lineup news after 2026-11-07 data cutoff materially shifts the line before kickoff
- reviewd1 is interpreted as the time series of the Kalshi KXNFLGAME-26NOV08NYGPHI-PHI contract price (i.e., the market-implied probability of a PHI win), given its value range (0.035-0.51), sample density through game day, and proximity to the as_of timestamp.
- reviewd3 (point spread series) and d4/d5/d6/d7 are auxiliary market/line-movement or injury-report style signals whose exact sign convention is unclear; I treat them as supporting context only, not as independent probability estimates.
- reviewd2's higher mean (~0.50) and stale last print (2026-11-03) suggest it is either a different book/market or a different variable on a different scale, not directly comparable to d1 as a probability.
- reviewNo access to late-breaking injury news (e.g., starting QB status) beyond what is embedded in the price series itself.
- reviewd6/d8 represent a market-implied probability (likely the Kalshi PHI-win contract price) rather than a Giants-side price, though this is not fully confirmed by the data labels.
- reviewd1/d3 are some rolling performance-margin metric (e.g., point differential or EPA differential) for PHI vs opponents, but the entity and sign convention are not explicitly labeled.
- reviewd5 is a point-spread-like series; its direction (favoring home or away) is ambiguous from the handle alone.
- reviewNo injury report, QB status, or weather data were supplied, so none of those confounders can be ruled in or out.
Simulated trade
The portfolio manager proposed no paper trade. Two independent disqualifiers. (1) No instrument in the available catalog (HENRY_HUB, UNG, XLE, VLO, MPC, PSX, CORN, BTC, ETH, WTI — all energy/commodity/crypto) references an NFL game or a sports-outcome contract; there is no venue in this book to express a PHI-vs-NYG view, so the question is structurally untradeable here regardless of conviction. (2) Even if a sports contract existed, the committee's own synthesis shows the 'consensus' of 0.51-0.53 is an artifact of averaging two mutually exclusive, unresolved readings of a single ambiguous data series (side-attribution PHI-favorite ~0.60 vs PHI-underdog ~0.39) rather than four independent confirmations. Treating that blended number as an edge against a resolved market price would be averaging-over-ambiguity, which the role's own methodology flags as improper. Required pre-trade step (not yet done by anyone): pull the actual contract/settlement metadata to resolve which side the price series refers to. Until that lookup happens AND a matching instrument exists in-book, expected return after costs is indistinguishable from zero with unknown sign, so no size is justified.
Forecasts
| Seat | Stage | P | Base | Resolves | Outcome | Brier |
|---|---|---|---|---|---|---|
| Committee | final | 51% | — | 2026-11-08 | No | 0.258 |
| Sports Analyst | prior | 68% | 57% | 2026-11-08 | No | 0.462 |
| Sports Analyst | independent | 58% | 57% | 2026-11-08 | No | 0.336 |
| Sports Analyst | revised | 52% | 57% | 2026-11-08 | No | 0.270 |
| Quantitative Researcher | prior | 65% | 60% | 2026-11-08 | No | 0.423 |
| Quantitative Researcher | independent | 60% | 60% | 2026-11-08 | No | 0.360 |
| Quantitative Researcher | revised | 46% | 60% | 2026-11-08 | No | 0.212 |
| Market Positioning Analyst | prior | 74% | 40% | 2026-11-08 | No | 0.548 |
| Market Positioning Analyst | independent | 40% | 40% | 2026-11-08 | No | 0.160 |
| Market Positioning Analyst | revised | 52% | 40% | 2026-11-08 | No | 0.270 |
| Causal Skeptic | prior | 72% | 57% | 2026-11-08 | No | 0.518 |
| Causal Skeptic | independent | 43% | 57% | 2026-11-08 | No | 0.185 |
| Causal Skeptic | revised | 53% | 57% | 2026-11-08 | No | 0.281 |